1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow RG6289 placebo: new trials by email Literature Review of RG6289 placebo trials Research Report on RG6289 placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease Donanemab, RG6289, Donanemab placebo - Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease | Phase 2 / Phase 3 | Recruiting | Banner Health | 240 | 2026-07-08 | 2026-09-02 |
Alzheimer Disease (1) · Dementia (1)
Banner Health (1)
Colombia (1)
Eric Reiman, M.D. (1) · Jessica Langbaum, Ph.D. (1) · Robert Alexander, M.D. (1) · Yakeel T. Quiroz-Gaviria, Ph.D. (1)
R01AG086363 (1)